I-Mab (NASDAQ:NBP) SVP Cong Claire Xu Sells 3,494 Shares of Stock

I-Mab (NASDAQ:NBP) SVP Cong Claire Xu sold 3,494 shares of I-Mab stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $3.94, for a total value of $13,766.36. Following the completion of the sale, the senior vice president directly owned 290,154 shares in the company, valued at $1,143,206.76. This represents a 1.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

I-Mab Stock Performance

NASDAQ NBP remained flat at $1.71 on Tuesday. The company’s stock had a trading volume of 756,514 shares, compared to its average volume of 894,712. The company’s fifty day simple moving average is $2.27. I-Mab has a 52 week low of $1.28 and a 52 week high of $6.79. The stock has a market capitalization of $197.76 million, a PE ratio of -4.75 and a beta of 1.48.

I-Mab (NASDAQ:NBP) last released its earnings results on Wednesday, April 8th. The company reported ($0.30) earnings per share (EPS) for the quarter. Equities analysts forecast that I-Mab will post -0.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NBP has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of I-Mab from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of I-Mab in a report on Wednesday, April 8th. Finally, Weiss Ratings downgraded shares of I-Mab from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 18th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

Hedge Funds Weigh In On I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Taikang Asset Management Hong Kong Co Ltd acquired a new stake in I-Mab (NASDAQ:NBP) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 128,765 shares of the company’s stock, valued at approximately $512,000. Taikang Asset Management Hong Kong Co Ltd owned about 0.11% of I-Mab at the end of the most recent quarter. 38.38% of the stock is currently owned by institutional investors and hedge funds.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.